

**Recombinant Interleukin-1 α , Interleukin-2 and M-CSF-1
enhance the survival of newborn C57BL/6 mice inoculated
intraperitoneally with a lethal dose of herpes simplex virus-1**

C. Berkowitz and Y. Becker

Department of Molecular Virology, Faculty of Medicine, Hebrew University of Jerusalem,
Jerusalem, Israel

Accepted September 27, 1991

Summary. Recombinant Interleukin-1 α (IL-1 α), Interleukin-2 (IL-2) and recombinant macrophage colony-stimulating factor-1 (M-CSF-1) as well as combinations of IL-2 and M-CSF-1 were studied for their ability to protect seven-day-old C57BL/6 mice against HSV-1 infection. Treatment of the mice with IL-2, M-CSF-1 or combinations of IL-2 and M-CSF-1 significantly increased survival rates. Treatment with IL-1 α (10 U and 100 U/mouse) was most effective in protection against HSV-1, resulting in significantly increased survival rates more than four times greater than the survival rate of the infected control group.

Introduction

Disseminated herpes simplex virus-1 (HSV-1) infection of newborns is a severe condition with mortality reaching as high as 15–20% in human neonates [13]. The outcome of HSV-1 infection can be influenced by the immunocompetency of the host. Defects in the immune system of neonates, possibly resulting in increased susceptibility to HSV-1 infection, have been identified both in humans and in the murine model. In the latter, most studies have been conducted with C57BL/6 mice which, at the age of four weeks, are resistant to intraperitoneal infection with HSV-1 as adults, but as newborns are highly susceptible [15, 32, 41]. Human studies suggest a delayed production of anti-HSV-1 antibody in neonates with low antibody-dependent cellular cytotoxicity (ADCC) as compared to adults [18]. The murine model reveals that newborn mice also have poor antibody responses to exogenous antigens [22]. However, administration of large doses of anti-HSV-1 antibodies immediately before or after infection with HSV-1 may alter the result of the infection [1, 3, 8, 26, 34]. Other immunologic defects previously described in newborn mice include defective macrophage function and impaired T-cell function, characterized by altered lym-

phokine production [14, 17]. Clearance of the virus from the peritoneum following intraperitoneal (i.p.) infection is accomplished largely by peritoneal macrophages [34]. The state of activation [2] and differentiation [35] of macrophages affects their ability to restrict HSV-1 replication in vitro [31]. When mature macrophages are absent from the peritoneum, the virus is able to penetrate the central nervous system, resulting in a lethal encephalitis in the mouse model [42]. Macrophages of neonate animals are unable to restrict viral replication [17]. Numerous attempts have been made to overcome these immunological defects. The transfer of peritoneal cells from nonimmune syngeneic adult mice to newborns results in reconstitution of the ability to produce antibodies [19]. This appears to be due to both macrophages and helper T-cell populations although the latter may be replaced with soluble helper T-cell products [19]. Lethal HSV-1 infection may be prevented either by administration of macrophages and T-cells or macrophages and T-cell-lymphokine-containing fraction [14]. T-cells may also be replaced with human recombinant interleukin-2 (IL-2) [14].

IL-1 plays an important role in local and generalized inflammatory and immune responses and has a wide spectrum of biological activities, including the induction of T-lymphocyte proliferation and the initiation of the acute phase response [5, 6]. It also stimulates the production of IL-2, IL-3, IL-6 and the interferon- γ [6] and acts in the augmentation of the immune response to antigens. Although originally described as a product of activated phagocytic cells, studies have shown that it is synthesized by numerous cell types. Expression of the IL-1 gene is induced in the course of antigen presentation to T cells [21]. IL-1 activity is encoded by two different genes, IL-1 α and IL-1 β . The murine cDNAs were cloned and shown to detect RNA species of 2.1 and 1.4 kb, respectively, by the Northern blot technique [9, 24]. Both species share the same range of biological activities [4, 6, 36] and bind to the same 80 kDa receptor [7].

IL-2 is secreted by T lymphocytes upon stimulation with mitogen or antigen and has effects on several immune functions including enhancement of natural killer (NK) cell activity, the induction of lymphokine-activated killer (LAK) cells and stimulation of interferon- γ production [40]. It also stimulates antiviral cytotoxicity of both adult and neonate human cells [20]. Human recombinant IL-2 (rIL-2) has previously been shown to protect against acute HSV-2 genital infections in guinea pigs [40] and is an effective immune therapy in neonatal mice when administered one day prior to infection [16]. Furthermore, the production of fully differentiated T-cells has an absolute requirement for IL-2. Resting T-cells do not make IL-2 nor do they respond to external sources of the factor. Both stimulation of IL-2 production and display of the IL-2 receptor requires the introduction of antigen.

Macrophage colony-stimulating factor (M-CSF-1) belongs to a group of growth factors that stimulate proliferation and differentiation of bone marrow progenitor cells and may also stimulate mature cells. Its primary role is macrophage activation [39]. Although IL-2 protection of newborn mice from HSV-

1 infection was reported [16, 17], no such studies were reported on the effect of M-CSF-1 on the resistance of newborn mice to HSV-1 infection. Since macrophages are known to possess receptors for both M-CSF-1 and IL-2 [11, 12], it is therefore possible that both cytokines might act to stimulate macrophage function. A combination of both cytokines may act synergistically to protect neonatal mice against lethal HSV-1 infection.

With the known interaction of various cytokines in the induction of the immune response in mind, we undertook the study of the protective effects of various concentrations of the recombinant cytokines IL-1 α , IL-2 and M-CSF-1 and combinations of IL-2 and M-CSF-1 on the outcome of lethal HSV-1 infection in 7-day-old C57BL/6 mice.

Materials and methods

Virus

Herpes simplex virus type 1 (HSV-1) KOS strain was obtained from Prof. F. Rapp, Pennsylvania State University, Hershey, U.S.A. The virus was propagated in BSC-1 cell cultures, grown in Dulbecco's modified Eagle's medium (DMEM, Gibco) containing 10% calf serum (Beth Haemek, Israel). Mice were injected intraperitoneally (i.p.) with either 10^3 or 10^4 pfu/mouse. Under these conditions, mortality occurs 2–3 days post infection (p.i.) and tapered off by day 7 in most cases.

Mice

C57BL/6 mice, aged 7 days at the start of the experiment were obtained from the Hebrew University animal facilities in litters of 8–10 pups. Each litter served as one experimental group. The total number of experiments with each experimental test group is indicated in Table 1.

Cytokines

IL-1 α , highly purified recombinant human interleukin-1 from *E. coli* containing 5×10^4 U/ml and > 95% pure by SDS-PAGE was purchased from Genzyme Corporation (Boston, MA). IL-2 (lot LSP-805), a highly purified recombinant human interleukin-2 from *E. coli* [28, 37] containing 18×10^6 international units/ml, was 99% pure by SDS-PAGE and contained 0.012 ng/ml endotoxin by the limulus amoeba lysate assay. M-CSF-1 (lot DP-403), a highly purified recombinant human macrophage Colony-Stimulating Factor [10, 23] containing 1.24×10^8 U/ml, was > 95% pure by SDS-PAGE and contained < 0.01 ng/ml endotoxin. These cytokines were generously provided by Cetus Corporation (Emeryville, CA). Dilutions of IL-2 and M-CSF-1 were carried out in DMEM and IL-1 α was diluted in sterile PBS containing 0.1% FCS as carrier protein. All cytokines were injected into the mice intraperitoneally (i.p.) at concentrations as indicated in Table 1.

Statistical analysis

Results of experiments were analyzed by χ^2 testing. Results were considered significant if $p < 0.05$.

Determination of virus in mouse brains

Brains of mice that died during the experiment were removed, homogenized in 1 ml DMEM, sonicated for 1 min and serially diluted in DMEM for titration on monolayers of BSC-1

cells in 12-well plates (Falcon). After adsorption for 1 h, monolayers were overlayed with 2% agar and 2 × DMEM (1:1 vol). After incubation for 3 days at 37 °C in a humidified atmosphere enriched with 5% CO₂, monolayers were fixed in 25% formaldehyde and stained with crystal violet.

Results

Seven-day-old C57BL/6 mice were injected intraperitoneally with IL-1 α , IL-2, M-CSF-1 or a combination of IL-2 and M-CSF-1 and were infected one day later with either 10³ pfu/mouse or 10⁴ pfu/mouse KOS strain HSV-1. Survival of the mice was recorded up to 21 days p.i.

Protective effect of IL-1 α

The results in Table 1 (mouse group 1) show that infection of untreated one-week-old C57BL/6 mice with 10³ pfu/mouse of the KOS strain of HSV-1 resulted

Table 1. Influence of cytokine treatment on survival rate of newborn mice infected with HSV-1 (10³ pfu/mouse)

Mouse group	Treatment	No. of experiments ^a	Survivors ^b /total	p-value ^c
1	Control: HSV-1 KOS	3	6/30	20
2	10 U IL-1 α ^d	2	18/20	90
3	100 U IL-1 α ^d	3	29/30	< 0.0001
4	1000 U IL-1 α ^d	1	3/10	30
5	Control: HSV-1 KOS	5	16/48	33
6	6 × 10 ³ U IL-2 ^e	4	23/38	61
7	6 × 10 ⁴ U IL-2 ^e	5	27/50	54
8	10 ³ U M-CSF-1 ^f	4	21/39	54
9	10 ⁴ U M-CSF-1 ^f	4	9/38	24
10	10 ⁵ U M-CSF-1 ^f	3	12/25	48
11	10 ⁶ U M-CSF-1 ^f	2	6/16	38
12	10 ⁶ U M-CSF-1 × 2 ^g	2	6/19	32
13	6 × 10 ³ U IL-2 + 10 ³ U M-CSF-1 ^h	2	15/20	75
14	6 × 10 ⁴ U IL-2 + 10 ⁶ U M-CSF-1 ^h	4	30/39	77

^a In each experiment one litter (10 newborn mice) was treated with the cytokines and subsequently inoculated with HSV-1 (KOS) at 10³ pfu/mouse

^b Total number of survivors on day 21 p.i. per total number of experimental animals in each group

^c χ^2 tests (groups 2 to 4 relative to control group 1, groups 6 to 14 relative to control group 5)

^d Animals received single doses of IL-1 α as indicated 24 h prior to virus infection

^e Animals received single doses of IL-2 as indicated 24 h prior to virus infection

^f Animals received single doses of M-CSF-1 as indicated 24 h prior to virus infection

^g Animals received single doses of M-CSF-1 as indicated

^h Animals received single doses of IL-2 and M-CSF-1 as indicated 24 h prior to virus infection

in a survival rate of 20% at 21 days p.i. Treatment of the neonates with IL-1 α at doses of 10 U/mouse or 100 U/mouse resulted in a highly significant increase in survival rates to 90% (mouse group 2, $p < 0.0001$) and 97% (mouse group 3, $p < 0.0001$), respectively. IL-1 α at doses of 1000 U/mouse resulted in a survival rate of 30% (mouse group 4, $p = 0.51$). These results are presented graphically in Fig. 1 A. Statistical comparison of the survival rate obtained after treatment with 10 U/mouse (mouse group 2) versus 100 U/mouse (mouse group 3) IL-1 α shows $p = 0.33$, an insignificant difference (Table 2). However, comparison of mouse group 2 (10 U/mouse IL-1 α) with group 4 (1000 U/mouse IL-1 α) or group 3 (100 U/mouse IL-1 α) with group 4 reveals highly significant p values of $p = 0.0007$ and $p < 0.0001$, respectively.

Protective effect of IL-2





The results for mouse group 5 (another set of controls) show that infection of untreated one-week-old C57BL/6 mice with 10^3 pfu/mouse of the KOS strain of HSV-1 resulted in a survival rate of 33% at 21 days p.i. Treatment of the neonates with either 6×10^3 U/mouse or 6×10^4 U/mouse of recombinant IL-2 (rIL-2) one day prior to infection (mouse groups 6 and 7, repeated 4 and 5 times respectively) resulted in a statistically significant increase in survival with survival rates of 61% ($p = 0.0119$) and 55% ($p = 0.0393$), respectively (represented in Fig. 1 B). The difference in survival rates between mouse groups 6 and 7 was not significant ($p = 0.64$).

Protective effect of M-CSF-1

Treatment with 10^3 U/mouse recombinant human M-CSF-1 (group 8, repeated four times) also resulted in a significant increase in survival to 54% ($p = 0.0543$), as compared to the survival of the untreated infected controls (group 5) (Fig. 1 C). Treatment with M-CSF-1 at doses of 10^4 U/mouse or 10^6 U/mouse (mouse groups 9, 10 and 11) or with two individual doses of M-CSF-1 10^6 U/mouse one day prior to and one day after infection (mouse group 12) showed no significant difference in survival rates relative to the control. In fact, administration of 10^4 U/mouse M-CSF-1 had an apparently deleterious effect, decreasing survival from 33% to 24% (mouse group 9). The reason for this effect is not known.

Protective effect of combinations of IL-2 and M-CSF-1

Injection of both IL-2 and M-CSF-1, administered one day prior to infection (mouse groups 13 and 14) significantly increased survival rates more than two-fold (to 75% survival, $p = 0.0017$), with no significant difference between a combination of 6×10^3 U/mouse IL-2 and 10^3 U/mouse M-CSF-1 (mouse group 13) or one of 6×10^4 U/mouse IL-2 and 10^6 U/mouse M-CSF-1 (mouse group 14) ($p = 0.87$) (results are represented graphically in Fig. 1 D). While a statistical comparison of the increase in survival rates between groups receiving 6×10^3



COPY

Table 2. Statistical comparison of survival rates of newborn mice pretreated with cytokines and infected with HSV-1

Mouse group ^a	Treatment	Survival		p-value ^b
		surv./total	%	
2	10 U IL-1 α	18/20	90	0.33
3	100 U IL-1 α	29/30	97	
2	10 U IL-1 α	18/20	90	0.0007
4	1000 U IL-1 α	3/10	30	
3	100 U IL-1 α	29/30	97	< 0.0001
4	1000 U IL-1 α	3/10	30	
6	6×10^3 U IL-2	23/38	61	0.27
13	6×10^3 U IL-2 + 10^3 U M-CSF-1	15/20	75	
7	6×10^4 U IL-2	25/50	54	0.025
14	6×10^4 U IL-2 + 10^6 U M-CSF-1	30/39	77	

^a Mouse groups same as in Table 1^b χ^2 tests

COPY

IL-2 alone or a combination of 6×10^3 U IL-2 and 10^3 U M-CSF-1 reveals an insignificant difference ($p = 0.27$). In Table 2, a comparison between the groups which received 6×10^4 U IL-2 and those which received a combination of 6×10^4 U IL-2 and 10^6 U M-CSF-1 shows $p = 0.025$, a moderately significant difference.

The effect of cytokines on the outcome of infection of one-week-old C57BL/6 mice with 10^4 pfu/mouse of the KOS strain of HSV-1 was also studied. This virus dose killed all the infected, untreated newborn mice. Treatment of the newborn mice with rIL-2 at 6×10^4 U/mouse prior to infection resulted in a highly significant increase in survival to 70% of the mice ($p = 0.0000$, to four decimal places) while M-CSF-1 at 10^3 U/mouse protected 30% of the mice ($p = 0.008$). A combination of rIL-2 at 6×10^4 U/mouse and M-CSF-1 at 10^6 U/mouse protected 60% ($p = 0.001$) of the mice. These results show that cytokine treatment is of protective value against a highly lethal dose of HSV-1.

Fig. 1A-D. Effect of cytokine treatment on the survival of newborn C57BL/6 mice infected with HSV-1. Mice were injected intraperitoneally with various doses of cytokines 24 h before intraperitoneal infection with 10^3 pfu/mouse of HSV-1 (KOS strain). Results are expressed in terms of percent survival. **A** Protective effects of IL-1 α treatment. **B** Protective effects of IL-2 treatment. **C** Protective effects of M-CSF-1 treatment. **D** Protective effects of combined cytokine treatment

Fate of virus in cytokine-treated mice

Virus content in brains from those newborn mice that were infected with HSV-1 and died during the observation period of 21 days was determined. Virus plaques were isolated from brain homogenates of the majority of infected newborn mice that succumbed to the virus infection, indicating that viral encephalitis was indeed the cause of death. Virus titres as high as 10^3 – 10^4 pfu/ml of brain suspension were recorded. This result is consistent with the observation of hind leg paralysis in many mice prior to death, indicating that the infecting virus penetrated the adrenal gland and the spinal cord and also infected the central nervous system [27]. No infectious virus was found in the brains of the HSV-1-inoculated neonatal mice that were protected by cytokines and survived the virus infection.

Discussion

The increased susceptibility of neonate animals and humans to lethal infection with HSV-1 may be due to a series of immunologic defects including defective macrophage function (with macrophages unable to process antigens) and impaired T-cell function. The role of T-cells may be replaced, at least in part, with IL-2.

Treatment with rIL-2 24 h prior to infection with HSV-1 provided the highest degree of protection, increasing survival to more than four times that of the control group. This 24 h period is needed to confer resistance of the newborn mice to HSV-1, coincides with the time period required for the protection of mice against *Pseudomonas aeruginosa* infection [37]. This time period allows IL-2 to activate T_h lymphocytes and macrophages, leading to an effective control of HSV-1 virus infection and spread in over 90% of the infected newborn mice.

Previous studies by Kohl et al. [16] have demonstrated that administration of recombinant human IL-2, optimally at doses of 100 U given one day prior to infection [17], provides effective immune therapy for neonatal HSV infection. Our results differ from those of Kohl [16, 17] regarding optimal dose of IL-2. We found rIL-2 at doses of 6×10^4 U/mouse to give maximal protection to neonate mice when administered one day prior to infection with HSV-1. However, differences in protection afforded by IL-2 at 6×10^3 U/mouse versus IL-2 at 6×10^4 U/mouse were not significant. An adjustment in the survival rate of mice treated with IL-2 at 6×10^4 U/mouse should be made as one set of ten mice died by day 6 post-infection and no virus was isolated from brain homogenates. However, a lethal infection of the adrenal glands cannot be ruled out as the cause of death prior to entry of the virus to the brain. If this group of ten mice is excluded from the calculations, we obtain a survival rate of 68%, instead of 54% (mouse group 7, Table 1).

Our results with M-CSF-1 revealed a slight increase in the survival rate of the newborn mice treated with the cytokine at doses of 10^3 U/mouse, but not at higher doses. Our findings suggest that M-CSF-1 stimulation of peritoneal

macrophages enhances the survival of the newborn mice and protect half of each litter against a lethal infection with HSV-1. Thus, stimulation of the immature peritoneal macrophages by M-CSF-1 has a protective value similar to that of IL-2 stimulation of immature T-cells in the newborn mice.

In this study, we showed that combinations of the recombinant cytokines IL-2 and M-CSF-1 that stimulate the immature T-cells and macrophages, respectively, provide a high degree of protection against infection with HSV-1. Survival rates greater than two times that of the control group were observed, suggesting that these two cytokines act synergistically to increase resistance of the newborn mice to HSV-1 infection. Yet, despite the marked ability of a combination of these cytokines to protect against infection, survival rates reached a maximum of only 77%, indicating that even these combination doses are not sufficient to confer full protection. Increasing the concentration of either cytokine in the combination dose appears to be ineffective, or even deleterious, (based on our results), thus the use of an additional cytokine such as IL-1 α might be used to further increase survival rates. The successful protection of newborn C57BL/6 mice against HSV-1 by recombinant IL-1, as shown in the present study, might be taken to suggest that induction of the maturation of macrophages and helper T-cells require the induction of intracellular molecular events in these cells which lead to the maturation of the cells and to their antiviral activity.

COPY

Acknowledgements

The authors wish to thank Dr. Peter Ralph and Jeffrey S. Price (Cetus Corporation, Emeryville, CA) for providing IL-2 and M-CSF-1 for the study and Dr. Richard Stanley, Department of Developmental Biology and Cancer, Albert Einstein College of Medicine, New York, for his interest and help. We also wish to thank Dr. Eli Sprecher for his suggestions and Dr. Jonathan Berkowitz for the statistical analysis. The support by the Foundation for the Study of Molecular Virology and Cell Biology, Arizona, U.S.A. is acknowledged.

References

1. Baron S, Worthington MG, Williams J, Gaines JW (1976) Postexposure serum prophylaxis of neonatal herpes simplex virus infection of mice. *Nature* 261: 505-506
2. Ben-Hur T, Rösen-Wolff A, Lamadé W, Darai G, Becker Y (1988) HSV-1 DNA sequence determining intraperitoneal pathogenicity in mice is required for transcription of viral immediate-early genes in macrophages. *Virology* 163: 397-404
3. Cho CT, Feng KK, Brahmacupta N (1976) Synergistic antiviral effects of adenine arabinoside and humoral antibodies in experimental encephalitis due to I *Herpesvirus hominis*. *J Infect Dis* 133: 157-167
4. De Luca D, Mizel SB (1986) Ia-positive nonlymphoid cells and T-cell development in murine fetal thymus organ cultures: interleukin-1 circumvents the block in T-cell differentiation induced by monoclonal anti-Ia antibodies. *J Immunol* 137: 1435-1441
5. Dinarello CA (1984) Interleukin-1. *Rev Infect Dis* 6: 51-95
6. Dinarello CA (1988) Biology of interleukin-1. *FASEB J* 2: 108-115
7. Dinarello CA, Clark BD, Puren AJ, Savage N, Rosoff PM (1989) The interleukin-1 receptor. *Immunol Today* 10: 49-51

8. Georgiades JA, Montgomery J, Hughes TK, Jensen D, Baron S (1982) Determinants of protection by human immune globulin against experimental herpes neonatorum (41433). *Proc Soc Exp Biol Med* 170: 291–297
9. Gray PW, Glaiser D, Chen E, Goeddel DV, Pennica D (1986) Two interleukin-1 genes in the mouse: cloning and expression of the cDNA for the murine interleukin-1 β . *J Immunol* 137: 3644–3648
10. Halenbeck R, Kawasaki E, Wrin J, Koths R (1989) Renaturation and purification of biological active recombinant human macrophage colony-stimulating factor expressed in *E. coli*. *Bio/Technology* 7: 710–715
11. Herrmann F, Cannistra SA, Levine H, Griffin JD (1985) Expression of interleukin-2 receptors and binding of interleukin-2 by gamma interferon-induced human leukemic and normal monocytic cells. *J Exp Med* 62: 1111–1116
12. Holter W, Goldman CK, Casabo L, Nelson DL, Greene WC, Waldmann TA (1987) Expression of functional IL-2 receptors by lipopolysaccharide and interferon- γ stimulated human monocytes. *J Immunol* 138: 2917–2922
13. Kohl S (1989) The neonatal human's immune response to herpes simplex virus infection: a critical review. *Pediatr Infect Dis* 8: 67–74
14. Kohl S, Cox PA, Loo LS (1987) Defective production of antibody to herpes simplex virus in neonates: defective production of T helper lymphokine and induction of suppression. *J Infect Dis* 155: 1179–1187
15. Kohl S, Loo LS (1980) Ontogeny of murine cellular cytotoxicity to herpes simplex virus-infected cells. *Infect Immun* 29: 847–853
16. Kohl S, Loo LS (1988) Use of interleukin-2 and macrophages to treat herpes simplex virus infection in neonatal mice. *J Infect Dis* 157: 1187–1192
17. Kohl S, Loo LS, Drath DB, Cox P (1989) Interleukin-2 protects neonatal mice from lethal herpes simplex virus infection: a macrophage-mediated, γ -interferon-induced mechanism. *J Infect Dis* 159: 239–244
18. Kohl S, Loo LS, Gonik B (1988) Analysis in human neonates of defective antibody-dependent cellular cytotoxicity and natural killer cytotoxicity to herpes simplex virus-infected cells. *J Infect Dis* 150: 14–19
19. Kohl S, Thomas JW, Loo LS (1986) Defective production of anti-herpes simplex virus antibody by neonatal mice. Reconstitution with Ia $^+$ macrophage and T helper lymphocytes from nonimmune adult syngeneic mice. *J Immunol* 136: 3038–3044
20. Kohl S, West MS, Loo LS (1988) Defects in interleukin-2 stimulation of neonatal natural killer cytotoxicity to herpes simplex virus-infected cells. *J Pediatr* 112: 976–981
21. Koide S, Steinman RM (1988) Induction of interleukin-1 mRNA during antigen-dependent interaction of sensitized T lymphoblasts with macrophages. *J Exp Med* 168: 409–416
22. Koyama H, Kasahara S (1975) Induction of herpes simplex virus immunity in newborn mice. *Infect Immun* 12: 1472–1474
23. Ladner MB, Martin GA, Noble JA, Nikoloff DM, Tal R, Kawasaki ES, White TJ (1987) Human CSF-1: gene structure and alternative splicing of mRNA precursors. *EMBO J* 6: 2693–2698
24. Lomedico PT, Gubler U, Hellman CP, Dukowich M, Giri JG, Pan YE, Collier K, Semiononov R, Chua AO, Mizel SB (1984) Cloning and expression of murine interleukin-1 cDNA in *E. coli*. *Nature* 312: 458–462
25. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA (1986) High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer. *JAMA* 256: 3117–3124
26. Luyet F, Samra D, Soneji A, Marks MI (1975) Passive immunization in experimental *Herpesvirus hominis* infection of newborn mice. *Infect Immun* 12: 1258–1261
27. Peles E, Rosen H, Darai G, Rösen-Wolff A, Becker Y (1990) Importance of the Hpa I-

- P sequence for herpes simplex virus-1 replication in the adrenal glands. *Arch Virol* 113: 151–163
28. Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark DF (1984) Biological activity of recombinant human interleukin-2 produced in *E. coli*. *Science* 223: 1412–1415
29. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Scipp CA, Reichert CM (1985) Observation on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. *N Engl J Med* 313: 1485–1492
30. Rosenstein M, Ettinghausen SE, Rosenberg SA (1986) Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. *J Immunol* 127: 1735–1742
31. Sarmiento M (1988) Intrinsic resistance to viral infection. Mouse macrophage restriction of herpes simplex virus replication. *J Immunol* 141: 2740–2748
32. Shellam GR, Flexman JP (1986) Genetically determined resistance to murine cytomegalovirus and herpes simplex virus in newborn mice. *J Virol* 58: 152–156
33. Sprecher E, Becker Y (1990) Induction of interleukin-1 α and β gene transcription in mouse peritoneal exudate cells after intraperitoneal infection with herpes simplex virus-1. *Arch Virol* 110: 259–269
34. Strulovitch C, Marks MI, Soneji A, Goldberg S (1979) Immunotherapy and drugs in neonatal murine herpetic simplex virus infection: a mouse model. *J Antimicrob Chemother* 25: 437–446
35. Tenner DJ, Morahan P (1987) Effect of differentiation of human macrophage-like U937 cells on intrinsic resistance to herpes simplex virus type 1. *J Immunol* 139: 3076–3083
36. Ulich TR, del Castillo J, Guo K, Soraia L (1989) The hematologic effects of chronic administration of the monokines tumor necrosis factor, interleukin-1 and granulocyte-stimulating colony factor on bone marrow circulation. *Am J Pathol* 143: 149–159
37. Van der Meer JWM, Barza M, Wolff SM, Dinarello CA (1988) A low dose of recombinant interleukin-1 protects granulocytopenic mice from a lethal Gram-negative infection. *Proc Natl Acad Sci USA* 85: 1620–1623
38. Wang A, Lu SD, Mark DF (1984) Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues. *Science* 224: 1431–1433
39. Warren MK, Ralph P (1986) Macrophage growth factor CSF-1 stimulates human monocyte production of interferon, tumor necrosis factor, and colony stimulating activity. *J Immunol* 137: 2281–2285
40. Weinberg A, Konrad M, Merrigam TC (1987) Regulation by recombinant interleukin-2 of protective immunity against recurrent herpes simplex virus type 2 genital infection in guinea pigs. *J Virol* 61: 2120–2127
41. Zawatzky R, Engler H, Kirchner H (1982) Experimental infection of inbred mice with herpes simplex virus. III. Comparisons between newborn and adult C57BL/6 mice. *J Gen Virol* 60: 25–29
42. Zisman B, Hirsh MS, Allison AC (1970) Selective effects of anti-macrophage serum, silica and anti-lymphocyte serum on pathogenesis of herpes simplex virus infection of young adult mice. *J Immunol* 104: 1155–1159

Authors' address: Dr. Y. Becker, Department of Molecular Virology, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Received September 25, 1991